In vitro evaluation of the efficacy of idarubicin in human tumour cells from patients with low-grade non-Hodgkin's lymphoma
| Autor: | Anna Åleskog, Elin Jonsson, Christer Sundström, Martin Höglund, Jörgen Kristensen, Rolf Larsson, Peter Nygren |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
Pathology Mitoxantrone Anthracycline Daunorubicin business.industry nutritional and metabolic diseases Hematology medicine.disease Gastroenterology Lymphoma Non-Hodgkin's lymphoma hemic and lymphatic diseases Internal medicine medicine Idarubicin Doxorubicin business Epirubicin medicine.drug |
| Zdroj: | British Journal of Haematology. 117:563-568 |
| ISSN: | 0007-1048 |
| DOI: | 10.1046/j.1365-2141.2002.03484.x |
| Popis: | Summary. Evaluating the potential benefit of the new anthracycline, idarubicin (Ida), in lymphoma, 58 tumour samples from patients suffering from low-grade non-Hodgkin's lymphoma (L-NHL), were analysed in vitro for their sensitivity to 0·5 µg/ml Ida. This was compared with the sensitivity to other anthracyclines (0·5 µg/ml), using the fluorometric microculture cytotoxicity assay. A total of 132 samples from patients with acute leukaemia and a cell-line panel representing different resistance mechanisms was included for comparison. The median cell survival of L-NHL cells did not differ after exposing the cells to Ida or daunorubicin (Dnr), whereas epirubicin, doxorubicin (Dox) and mitoxantrone (Mitox) were significantly less cytotoxic than Ida (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text